open access

Vol 49, No 2 (2011)
Original paper
Published online: 2011-07-11
Submitted: 2011-12-19
Get Citation

Selective gene expression profiling of mTOR-associated tumor suppressor and oncogenes in ovarian cancer

Piotr Laudański, Oksana Kowalczuk, Dagmara Klasa-Mazurkiewicz, Tomasz Milczek, Dominik Rysak-Luberowicz, Magdalena Garbowicz, Włodzimierz Baranowski, Radosław Charkiewicz, Jacek Szamatowicz, Lech Chyczewski
DOI: 10.5603/FHC.2011.0044
·
Folia Histochem Cytobiol 2011;49(2):317-324.

open access

Vol 49, No 2 (2011)
ORIGINAL PAPERS
Published online: 2011-07-11
Submitted: 2011-12-19

Abstract

The aim of this study was to selectively profile the activation status of mammalian target of rapamycin (mTOR)-associated oncogenes and tumor suppressor genes (TSGs) in ovarian cancer specimens, healthy ovaries and benign ovarian tumors, including endometrial cysts. We used a novel type of microfluidic gene array to examine the expression of 15 human tumor suppressors and oncogenes in ovarian cancer specimens of 53 patients, benign ovarian cysts of 29 women (endometrial and simple) and 11 healthy ovaries of individuals in whom the material was obtained during total hysterectomies performed because of fibroid changes. The array was custom-designed to include the following genes: NF1, RHEB, mTOR1, AKT-1, PTEN, TSC1, TSC2, KRAS, RPS6KB1, 4EBP1, TP53, EIF4E, STK11, PIK3CA and BECN1. Confirmatory immunohistochemical detection was performed for a group of selected proteins. Particularly significant differences were observed as to the expression of PTEN (p < 0.0001), TP53 (p = 0.0003), PIK3CA (p = 0.0003) and BECN1 (p = 0.0014) which were shown to be downregulated in cancer patients when compared to healthy ovaries and benign ovarian cysts (endometrial and simple). These markers did not show association with grade or stage of the tumor. Immunohistochemistry showed that PTEN, TP53, PIK3CA and BECN1 proteins are expressed in ovarian cancer. Our results indicate that there are significant differences in the expression of some of the mTOR-related tumor suppressors and oncogenes which could be associated with the pathogenesis of ovarian cancer. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 2, pp. 317–324)

Abstract

The aim of this study was to selectively profile the activation status of mammalian target of rapamycin (mTOR)-associated oncogenes and tumor suppressor genes (TSGs) in ovarian cancer specimens, healthy ovaries and benign ovarian tumors, including endometrial cysts. We used a novel type of microfluidic gene array to examine the expression of 15 human tumor suppressors and oncogenes in ovarian cancer specimens of 53 patients, benign ovarian cysts of 29 women (endometrial and simple) and 11 healthy ovaries of individuals in whom the material was obtained during total hysterectomies performed because of fibroid changes. The array was custom-designed to include the following genes: NF1, RHEB, mTOR1, AKT-1, PTEN, TSC1, TSC2, KRAS, RPS6KB1, 4EBP1, TP53, EIF4E, STK11, PIK3CA and BECN1. Confirmatory immunohistochemical detection was performed for a group of selected proteins. Particularly significant differences were observed as to the expression of PTEN (p < 0.0001), TP53 (p = 0.0003), PIK3CA (p = 0.0003) and BECN1 (p = 0.0014) which were shown to be downregulated in cancer patients when compared to healthy ovaries and benign ovarian cysts (endometrial and simple). These markers did not show association with grade or stage of the tumor. Immunohistochemistry showed that PTEN, TP53, PIK3CA and BECN1 proteins are expressed in ovarian cancer. Our results indicate that there are significant differences in the expression of some of the mTOR-related tumor suppressors and oncogenes which could be associated with the pathogenesis of ovarian cancer. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 2, pp. 317–324)
Get Citation

Keywords

ovarian cancer; mTOR pathway; TP53; PIK3CA; PTEN; BECN1

About this article
Title

Selective gene expression profiling of mTOR-associated tumor suppressor and oncogenes in ovarian cancer

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 49, No 2 (2011)

Article type

Original paper

Pages

317-324

Published online

2011-07-11

DOI

10.5603/FHC.2011.0044

Bibliographic record

Folia Histochem Cytobiol 2011;49(2):317-324.

Keywords

ovarian cancer
mTOR pathway
TP53
PIK3CA
PTEN
BECN1

Authors

Piotr Laudański
Oksana Kowalczuk
Dagmara Klasa-Mazurkiewicz
Tomasz Milczek
Dominik Rysak-Luberowicz
Magdalena Garbowicz
Włodzimierz Baranowski
Radosław Charkiewicz
Jacek Szamatowicz
Lech Chyczewski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl